The role of tumor necrosis factor- eceptors in pregnancy with normal and adverse outcome

International Journal of Interferon, Cytokine and Mediator Research

Volumn 4, Issue 1, 2012, Pages

  Calleja Agius, Jean ^a   Muttukrishna, Shanthi ^b   Jauniaux, Eric ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Miscarriage; Preeclampsia; Pregnancy; Preterm labor; Receptors; TNF

Indexed keywords

CASPASE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADVERSE OUTCOME; AMNIONITIS; APOPTOSIS; BIRTH DEFECT; CHORIOAMNIONITIS; CYTOKINE RELEASE; DNA POLYMORPHISM; DOWN REGULATION; FIRST TRIMESTER PREGNANCY; GENE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HIGH RISK PREGNANCY; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PREECLAMPSIA; PREGNANCY COMPLICATION; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR BINDING; REVIEW; SPONTANEOUS ABORTION; TH1 TH2 BALANCE; TUMOR NECROSIS FACTOR ALPHA GENE; UPREGULATION;

EID: 84856980281     PISSN: None     EISSN: 1179139X     Source Type: Journal    
DOI: None     Document Type: Review

References (206)

1. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;17(3):138-146.
2. Coffman RL, Romagnani S. Redirection of Th1 and Th2 Responses. Berlin: Springer-Verlag; 1999.
3. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today. 1993;14(7):353-356.
4. Wilczynski JR. Th1/Th2 cytokines balance - yin and yang of reproductive immunology. Eur J Obstet Gynecol Reprod Biol. 2005;122(2): 136-143.
5. Raghupathy R. Pregnancy: success and failure within the Th1/Th2/Th3 paradigm. Semin Immunol. 2001;13(4):219-227.
6. Chaouat G. The Th1/Th2 paradigm: still important in pregnancy? Semin Immunopathol. 2007;29(2):95-113.
7. Sacks GP, Studena K, Sargent K, Redman CW. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol. 1998;179(1):80-86.
8. Kirwan JP, Hauguel-De Mouzon S, Lepercq J, et al. TNF-alpha is a predictor of insulin resistance in human pregnancy. Diabetes. 2002;51(7):2207-2213.
9. Haider S, Knofler M. Human tumour necrosis factor: physiological and pathological roles in placenta and endometrium. Placenta. 2009;30(2):111-123.
10. Terranova PF, Hunter VJ, Roby KF, Hunt JS. Tumor necrosis factor-alpha in the female reproductive tract. Proc Soc Exp Biol Med. 1995;209(4):325-342.
11. Hohmann HP, Remy R, Brockhaus M, van Loon AP. Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha). J Biol Chem. 1989;264(25): 14927-14934.
12. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A. 1990;87(8):3127-3131.
13. Leeuwenberg JF, van Tits LJ, Jeunhomme TM, Buurman WA. Evidence for exclusive role in signalling of tumour necrosis factor p55 receptor and a potentiating function of p75 receptor on human endothelial cells. Cytokine. 1995;7(5):457-462.
14. Bigda J, Beletsky I, Brakebusch C, et al. Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity. J Exp Med. 1994; 180(2):445-460.
15. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 1995;5(10): 392-399.
16. Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995;83(5):793-802.
17. Wong GH, Tartaglia LA, Lee MS, Goeddel DV. Antiviral activity of tumor necrosis factor is signaled through the 55-kDa type I TNF receptor [corrected]. J Immunol. 1992;149(10):3350-3353.
18. Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214(2): 149-160.
19. Heller RA, Song K, Fan N, Chang DJ. The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell. 1992;70(1):47-56.
20. Barbara JA, Smith WB, Gamble JR, et al. Dissociation of TNFalpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants. EMBO J. 1994;13(4): 843-850.
21. Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEB J. 1991;5(11):2567-2574.
22. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385(6618):729-733.
23. Van O, X, Tavernier J, Fiers W. Structure-activity studies of human tumour necrosis factors. Protein Eng. 1994;7(1):5-22.
24. Bemelmans MH, Gouma DJ, Buurman WA. LPS-induced sTNFreceptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma. J Immunol. 1993;151(10):5554-5562.
25. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97(1):133-144.
26. Chen HL, Yang YP, Hu XL, Yelavarthi KK, Fishback JL, Hunt JS. Tumor necrosis factor alpha mRNA and protein are present in human placental and uterine cells at early and late stages of gestation. Am J Pathol. 1991;139(2):327-335.
27. Hunt JS, Chen HL, Hu XL, Tabibzadeh S. Tumor necrosis factor-alpha messenger ribonucleic acid and protein in human endometrium. Biol Reprod. 1992;47(1):141-147.
28. Hunt JS, Chen HL, Miller L. Tumor necrosis factors: pivotal components of pregnancy? Biol Reprod. 1996;54(3):554-562.
29. Vince G, Shorter S, Starkey P, et al. Localization of tumour necrosis factor production in cells at the materno/fetal interface in human pregnancy. Clin Exp Immunol. 1992;88(1):174-180.
30. Jokhi PP, King A, Sharkey AM, Smith SK, Loke YW. Screening for cytokine messenger ribonucleic acids in purified human decidual lymphocyte populations by the reverse-transcriptase polymerase chain reaction. J Immunol. 1994;153(10):4427-4435.
31. Tabibzadeh S. Ubiquitous expression of TNF-alpha/cachectin immunoreactivity in human endometrium. Am J Reprod Immunol. 1991;26(1):1-4.
32. Jokhi PP, King A, Loke YW. Cytokine production and cytokine receptor expression by cells of the human first trimester placental-uterine interface. Cytokine. 1997;9(2):126-137.
33. Gustafsson C, Hummerdal P, Matthiesen L, Berg G, Ekerfelt C, Ernerudh J. Cytokine secretion in decidual mononuclear cells from term human pregnancy with or without labour: ELISPOT detection of IFN-gamma, IL-4, IL-10, TGF-beta and TNF-alpha. J Reprod Immunol. 2006;71(1):41-56.
34. Menon R, Velez DR, Morgan N, Lombardi SJ, Fortunato SJ, Williams SM. Genetic regulation of amniotic fluid TNF-alpha and soluble TNF receptor concentrations affected by race and preterm birth. Hum Genet. 2008;124(3):243-253.
35. Chow SS, Craig ME, Jones CA, et al. Differences in amniotic fluid and maternal serum cytokine levels in early midtrimester women without evidence of infection. Cytokine. 2008;44(1):78-84.
36. Menon R, Thorsen P, Vogel I, et al. Racial disparity in amniotic fluid concentrations of tumor necrosis factor (TNF)-alpha and soluble TNF receptors in spontaneous preterm birth. Am J Obstet Gynecol. 2008;198(5):533-510.
37. Thomakos N, Daskalakis G, Papapanagiotou A, Papantoniou N, Mesogitis S, Antsaklis A. Amniotic fluid interleukin-6 and tumor necrosis factor-alpha at mid-trimester genetic amniocentesis: relationship to intra-amniotic microbial invasion and preterm delivery. Eur J Obstet Gynecol Reprod Biol. 2010;148(2):147-151.
38. Hayashi M, Ueda Y, Yamaguchi T, et al. Tumor necrosis factor-alpha in the placenta is not elevated in pre-eclamptic patients despite its elevation in peripheral blood. Am J Reprod Immunol. 2005;53(3):113-119.
39. Opsjon SL, Novick D, Wathen NC, Cope AP, Wallach D, Aderka D. Soluble tumor necrosis factor receptors and soluble interleukin-6 receptor in fetal and maternal sera, coelomic and amniotic fluids in normal and pre-eclamptic pregnancies. J Reprod Immunol. 1995;29(2):119-134.
40. Aaltonen R, Heikkinen T, Hakala K, Laine K, Alanen A. Transfer of proinflammatory cytokines across term placenta. Obstet Gynecol. 2005;106(4):802-807.
41. Jaattela M, Kuusela P, Saksela E. Demonstration of tumor necrosis factor in human amniotic fluids and supernatants of placental and decidual tissues. Lab Invest. 1988;58(1):48-52.
42. Hunt JS. Expression and regulation of the tumour necrosis factoralpha gene in the female reproductive tract. Reprod Fertil Dev. 1993; 5(2):141-153.
43. King A, Jokhi PP, Smith SK, Sharkey AM, Loke YW. Screening for cytokine mRNA in human villous and extravillous trophoblasts using the reverse-transcriptase polymerase chain reaction (RT-PCR). Cytokine. 1995;7(4):364-371.
44. Yang Y, Yelavarthi KK, Chen HL, Pace JL, Terranova PF, Hunt JS. Molecular, biochemical, and functional characteristics of tumor necrosis factor-alpha produced by human placental cytotrophoblastic cells. J Immunol. 1993;150(12):5614-5624.
45. Li Y, Matsuzaki N, Masuhiro K, et al. Trophoblast-derived tumor necrosis factor-alpha induces release of human chorionic gonadotropin using interleukin-6 (IL-6) and IL-6-receptor-dependent system in the normal human trophoblasts. J Clin Endocrinol Metab. 1992;74(1):184-191.
46. Brosens JJ, Pijnenborg R, Brosens IA. The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature. Am J Obstet Gynecol. 2002;187(5):1416-1423.
47. Hering L, Herse F, Verlohren S, et al. Trophoblasts reduce the vascular smooth muscle cell proatherogenic response. Hypertension. 2008;51(2):554-559.
48. Knofler M, Mosl B, Bauer S, Griesinger G, Husslein P. TNF-alpha/ TNFRI in primary and immortalized first trimester cytotrophoblasts. Placenta. 2000;21(5-6):525-535.
49. Yelavarthi KK, Hunt JS. Analysis of p60 and p80 tumor necrosis factoralpha receptor messenger RNA and protein in human placentas. Am J Pathol. 1993;143(4):1131-1141.
50. Austgulen R, Espevik T, Mecsei R, Scott H. Expression of receptors for tumor necrosis factor in human placenta at term. Acta Obstet Gynecol Scand. 1992;71(6):417-424.
51. Rutherford MS, Schook LB. Differential immunocompetence of macrophages derived using macrophage or granulocyte-macrophage colony-stimulating factor. J Leukoc Biol. 1992;51(1):69-76.
52. Renaud SJ, Sullivan R, Graham CH. Tumour necrosis factor alpha stimulates the production of monocyte chemoattractants by extravillous trophoblast cells via differential activation of MAPK pathways. Placenta. 2009;30(4):313-319.
53. Denney JM, Nelson EL, Wadhwa PD, et al. Longitudinal modulation of immune system cytokine profile during pregnancy. Cytokine. 2010; 53(2):170-177.
54. Aris A, Lambert F, Bessette P, Moutquin JM. Maternal circulating interferon-gamma and interleukin-6 as biomarkers of Th1/Th2 immune status throughout pregnancy. J Obstet Gynaecol Res. 2008; 34(1):7-11.
55. Beckmann I, Visser W, Struijk PC, van Dooren M, Glavimans J, Wallenburg HC. Circulating bioactive tumor necrosis factor-alpha, tumor necrosis factor-alpha receptors, fibronectin, and tumor necrosis factor-alpha inducible cell adhesion molecule VCAM-1 in uncomplicated pregnancy. Am J Obstet Gynecol. 1997;177(5):1247-1252.
56. Hung TH, Charnock-Jones DS, Skepper JN, Burton GJ. Secretion of tumor necrosis factor-alpha from human placental tissues induced by hypoxia-reoxygenation causes endothelial cell activation in vitro: a potential mediator of the inflammatory response in preeclampsia. Am J Pathol. 2004;164(3):1049-1061.
57. Pijnenborg R, McLaughlin PJ, Vercruysse L, et al. Immunolocalization of tumour necrosis factor-alpha (TNF-alpha) in the placental bed of normotensive and hypertensive human pregnancies. Placenta. 1998;19(4):231-239.
58. Yui J, Hemmings D, Garcia-Lloret M, Guilbert LJ. Expression of the human p55 and p75 tumor necrosis factor receptors in primary villous trophoblasts and their role in cytotoxic signal transduction. Biol Reprod. 1996;55(2):400-409.
59. Austgulen R, Liabakk NB, Brockhaus M, Espevik T. Soluble TNF receptors in amniotic fluid and in urine from pregnant women. J Reprod Immunol. 1992;22(2):105-116.
60. Knofler M, Stenzel M, Husslein P. Shedding of tumour necrosis factor receptors from purified villous term trophoblasts and cytotrophoblastic BeWo cells. Hum Reprod. 1998;13(8):2308-2316.
61. Joyce DA, Gibbons DP, Green P, Steer JH, Feldmann M, Brennan FM. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol. 1994;24(11):2699-2705.
62. Pressman EK, Thornburg LL, Glantz JC, et al. Inflammatory cytokines and antioxidants in midtrimester amniotic fluid: correlation with pregnancy outcome. Am J Obstet Gynecol. 2011;204(2):155-157.
63. Beutler B, Grau GE. Tumor necrosis factor in the pathogenesis of infectious diseases. Crit Care Med. 1993;21(Suppl 10):S423-S435.
64. Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol. 2006;7(4):354-359.
65. Shaarawy M, Nagui AR. Enhanced expression of cytokines may play a fundamental role in the mechanisms of immunologically mediated recurrent spontaneous abortion. Acta Obstet Gynecol Scand. 1997;76(3):205-211.
66. Chernyshov VP, Vodyanik MA, Pisareva SP. Lack of soluble TNFreceptors in women with recurrent spontaneous abortion and possibility for its correction. Am J Reprod Immunol. 2005;54(5):284-291.
67. Winger EE, Reed JL. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol. 2008;60(1):8-16.
68. Arck P, Dietl J, Clark D. From the decidual cell internet: trophoblastrecognizing T cells. Biol Reprod. 1999;60(2):227-233.
69. Faye A, Pornprasert S, Dolcini G, et al. Evaluation of the placental environment with a new in vitro model of histocultures of early and term placentae: determination of cytokine and chemokine expression profiles. Placenta. 2005;26(2-3):262-267.
70. Carpentier PA, Dingman AL, Palmer TD. Placental TNF-alpha signaling in illness-induced complications of pregnancy. Am J Pathol. 2011;178(6):2802-2810.
71. Hirota Y, Cha J, Dey SK. Revisiting reproduction: Prematurity and the puzzle of progesterone resistance. Nat Med. 2010;16(5):529-531.
72. Kim YM, Chaiworapongsa T, Gomez R, et al. Failure of physiologic transformation of the spiral arteries in the placental bed in preterm premature rupture of membranes. Am J Obstet Gynecol. 2002;187(5): 1137-1142.
73. Hung TH, Burton GJ. Hypoxia and reoxygenation: a possible mechanism for placental oxidative stress in preeclampsia. Taiwan J Obstet Gynecol. 2006;45(3):189-200.
74. Christiaens I, Zaragoza DB, Guilbert L, Robertson SA, Mitchell BF, Olson DM. Inflammatory processes in preterm and term parturition. J Reprod Immunol. 2008;79(1):50-57.
75. Dudley DJ. Immunoendocrinology of preterm labor: the link between corticotropin-releasing hormone and inflammation. Am J Obstet Gynecol. 1999;180(1 Pt 3):S251-S256.
76. Ulug U, Goldman S, Ben-Shlomo I, Shalev E. Matrix metalloproteinase (MMP)-2 and MMP-9 and their inhibitor, TIMP-1, in human term decidua and fetal membranes: the effect of prostaglandin F(2alpha) and indomethacin. Mol Hum Reprod. 2001;7(12): 1187-1193.
77. Jacobsson B, Mattsby-Baltzer I, Andersch B, et al. Microbial invasion and cytokine response in amniotic fluid in a Swedish population of women with preterm prelabor rupture of membranes. Acta Obstet Gynecol Scand. 2003;82(5):423-431.
78. Shobokshi A, Shaarawy M. Maternal serum and amniotic fluid cytokines in patients with preterm premature rupture of membranes with and without intrauterine infection. Int J Gynaecol Obstet. 2002;79(3):209-215.
79. Menon R, Swan KF, Lyden TW, Rote NS, Fortunato SJ. Expression of inflammatory cytokines (interleukin-1 beta and interleukin-6) in amniochorionic membranes. Am J Obstet Gynecol. 1995;172(2 Pt 1): 493-500.
80. Fortunato SJ, Menon R, Lombardi SJ. Role of tumor necrosis factor-alpha in the premature rupture of membranes and preterm labor pathways. Am J Obstet Gynecol. 2002;187(5):1159-1162.
81. Menon R, Lombardi SJ, Fortunato SJ. TNF-alpha promotes caspase activation and apoptosis in human fetal membranes. J Assist Reprod Genet. 2002;19(4):201-204.
82. Luo G, Abrahams VM, Tadesse S, et al. Progesterone inhibits basal and TNF-alpha-induced apoptosis in fetal membranes: a novel mechanism to explain progesterone-mediated prevention of preterm birth. Reprod Sci. 2010;17(6):532-539.
83. Xaus J, Comalada M, Valledor AF, et al. LPS induces apoptosis in macrophages mostly through the autocrine production of TNF-alpha. Blood. 2000;95(12):3823-3831.
84. Keelan JA, Khan S, Yosaatmadja F, Mitchell MD. Prevention of inflammatory activation of human gestational membranes in an ex vivo model using a pharmacological NF-kappaB inhibitor. J Immunol. 2009;183(8):5270-5278.
85. Romero R, Manogue KR, Mitchell MD, et al. Infection and labor. IV. Cachectin-tumor necrosis factor in the amniotic fluid of women with intraamniotic infection and preterm labor. Am J Obstet Gynecol. 1989;161(2):336-341.
86. Romero R, Espinoza J, Kusanovic JP, et al. The preterm parturition syndrome. BJOG. 2006;113 Suppl 3:17-42.
87. Casey ML, Cox SM, Word RA, MacDonald PC. Cytokines and infection-induced preterm labour. Reprod Fertil Dev. 1990;2(5): 499-509.
88. Fortunato SJ, Menon R, Swan KF. Expression of TNF-alpha and TNFR p55 in cultured amniochorion. Am J Reprod Immunol. 1994;32(3):188-193.
89. Romero R, Avila C, Santhanam U, Sehgal PB. Amniotic fluid interleukin 6 in preterm labor. Association with infection. J Clin Invest. 1990;85(5):1392-1400.
90. Hillier SL, Witkin SS, Krohn MA, Watts DH, Kiviat NB, Eschenbach DA. The relationship of amniotic fluid cytokines and preterm delivery, amniotic fluid infection, histologic chorioamnionitis, and chorioamnion infection. Obstet Gynecol. 1993;81(6):941-948.
91. Houben ML, Nikkels PG, van Bleek GM, et al. The association between intrauterine inflammation and spontaneous vaginal delivery at term: a cross-sectional study. PloS One. 2009;4(8):e6572.
92. Ojeda OM, Silva CV, de JAR, Fernandez-Ortega C. TNFalpha production in whole blood cultures from healthy individuals. Biochem Biophys Res Commun. 2002;292(2):538-541.
93. Romero R, Mazor M, Sepulveda W, Avila C, Copeland D, Williams J. Tumor necrosis factor in preterm and term labor. Am J Obstet Gynecol. 1992;166(5):1576-1587.
94. Maymon E, Ghezzi F, Edwin SS, et al. The tumor necrosis factor alpha and its soluble receptor profile in term and preterm parturition. Am J Obstet Gynecol. 1999;181(5 Pt 1):1142-1148.
95. Fortunato SJ, Menon R. Distinct molecular events suggest different pathways for preterm labor and premature rupture of membranes. Am J Obstet Gynecol. 2001;184(7):1399-1405.
96. Romero R, Mazor M. Infection and preterm labor. Clin Obstet Gynecol. 1988;31(3):553-584.
97. Zaga-Clavellina V, Garcia-Lopez G, Flores-Herrera H, et al. In vitro secretion profiles of interleukin (IL)-1beta, IL-6, IL-8, IL-10, and TNF alpha after selective infection with Escherichia coli in human fetal membranes. Reprod Biol Endocrinol. 2007;5:46.
98. Romero R, Chaiworapongsa T, Kuivaniemi H, Tromp G. Bacterial vaginosis, the inflammatory response and the risk of preterm birth: a role for genetic epidemiology in the prevention of preterm birth. Am J Obstet Gynecol. 2004;190(6):1509-1519.
99. El-Bastawissi AY, Williams MA, Riley DE, Hitti J, Krieger JN. Amniotic fluid interleukin-6 and preterm delivery: a review. Obstet Gynecol. 2000;95(6 Pt 2):1056-1064.
100. Yoon BH, Romero R, Moon JB, et al. Clinical significance of intraamniotic inflammation in patients with preterm labor and intact membranes. Am J Obstet Gynecol. 2001;185(5):1130-1136.
101. Sadowsky DW, Adams KM, Gravett MG, Witkin SS, Novy MJ. Preterm labor is induced by intraamniotic infusions of interleukin- 1beta and tumor necrosis factor-alpha but not by interleukin-6 or interleukin-8 in a nonhuman primate model. Am J Obstet Gynecol. 2006;195(6):1578-1589.
102. Lappas M, Permezel M, Rice GE. Advanced glycation endproducts mediate pro-inflammatory actions in human gestational tissues via nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. J Endocrinol. 2007;193(2):269-277.
103. Molnar M, Romero R, Hertelendy F. Interleukin-1 and tumor necrosis factor stimulate arachidonic acid release and phospholipid metabolism in human myometrial cells. Am J Obstet Gynecol. 1993;169(4):825-829.
104. Wenstrom KD, Andrews WW, Hauth JC, Goldenberg RL, DuBard MB, Cliver SP. Elevated second-trimester amniotic fluid interleukin-6 levels predict preterm delivery. Am J Obstet Gynecol. 1998;178(3): 546-550.
105. Goepfert AR, Goldenberg RL, Andrews WW, et al. The Preterm Prediction Study: association between cervical interleukin 6 concentration and spontaneous preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol. 2001;184(3):483-488.
106. Genc MR, Witkin SS, Delaney ML, et al. A disproportionate increase in IL-1beta over IL-1ra in the cervicovaginal secretions of pregnant women with altered vaginal microflora correlates with preterm birth. Am J Obstet Gynecol. 2004;190(5):1191-1197.
107. Gargano JW, Holzman C, Senagore P, et al. Mid-pregnancy circulating cytokine levels, histologic chorioamnionitis and spontaneous preterm birth. J Reprod Immunol. 2008;79(1):100-110.
108. El-Shazly S, Makhseed M, Azizieh F, Raghupathy R. Increased expression of pro-inflammatory cytokines in placentas of women undergoing spontaneous preterm delivery or premature rupture of membranes. Am J Reprod Immunol. 2004;52(1):45-52.
109. Holzman C, Lin X, Senagore P, Chung H. Histologic chorioamnionitis and preterm delivery. Am J Epidemiol. October 1, 2007; 166(7):786-794.
110. Goldenberg RL, Iams JD, Mercer BM, et al. The Preterm Prediction Study: toward a multiple-marker test for spontaneous preterm birth. Am J Obstet Gynecol. 2001;185(3):643-651.
111. Curry AE, Vogel I, Skogstrand K, et al. Maternal plasma cytokines in early- and mid-gestation of normal human pregnancy and their association with maternal factors. J Reprod Immunol. 2008;77(2):152-160.
112. Curry AE, Vogel I, Drews C, et al. Mid-pregnancy maternal plasma levels of interleukin 2, 6, and 12, tumor necrosis factor-alpha, interferon-gamma, and granulocyte-macrophage colony-stimulating factor and spontaneous preterm delivery. Acta Obstet Gynecol Scand. 2007;86(9):1103-1110.
113. Bahar AM, Ghalib HW, Moosa RA, Zaki ZM, Thomas C, Nabri OA. Maternal serum interleukin-6, interleukin-8, tumor necrosis factoralpha and interferon-gamma in preterm labor. Acta Obstet Gynecol Scand. 2003;82(6):543-549.
114. Peltier MR. Immunology of term and preterm labor. Reprod Biol Endocrinol. 2003;1:122.
115. Baggia S, Gravett MG, Witkin SS, Haluska GJ, Novy MJ. Interleukin-1 beta intra-amniotic infusion induces tumor necrosis factor-alpha, prostaglandin production, and preterm contractions in pregnant rhesus monkeys. J Soc Gynecol Investig. 1996;3(3):121-126.
116. Silver RM, Lohner WS, Daynes RA, Mitchell MD, Branch DW. Lipopolysaccharide-induced fetal death: the role of tumor-necrosis factor alpha. Biol Reprod. 1994;50(5):1108-1112.
117. Holmgren C, Esplin MS, Hamblin S, Molenda M, Simonsen S, Silver R. Evaluation of the use of anti-TNF-alpha in an LPS-induced murine model. J Reprod Immunol. 2008;78(2):134-139.
118. Menon R, Merialdi M, Betran AP, et al. Analysis of association between maternal tumor necrosis factor-alpha promoter polymorphism (-308), tumor necrosis factor concentration, and preterm birth. Am J Obstet Gynecol. 2006;195(5):1240-1248.
119. Macones GA, Parry S, Elkousy M, Clothier B, Ural SH, Strauss JF III. A polymorphism in the promoter region of TNF and bacterial vaginosis: preliminary evidence of gene-environment interaction in the etiology of spontaneous preterm birth. Am J Obstet Gynecol. 2004;190(6):1504-1508.
120. Amory JH, Hitti J, Lawler R, Eschenbach DA. Increased tumor necrosis factor-alpha production after lipopolysaccharide stimulation of whole blood in patients with previous preterm delivery complicated by intra-amniotic infection or inflammation. Am J Obstet Gynecol. 2001;185(5):1064-1067.
121. Peltier MR, Faux DS, Hamblin SD, Silver RM, Esplin MS. Cytokine production by peripheral blood mononuclear cells of women with a history of preterm birth. J Reprod Immunol. 2010;84(1):111-116.
122. Menon R, Thorsen P, Vogel I, Jacobsson B, Williams SM, Fortunato SJ. Increased bioavailability of TNF-alpha in African Americans during in vitro infection: predisposing evidence for immune imbalance. Placenta. 2007;28(8-9):946-950.
123. Reddy P, Slack JL, Davis R, et al. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem. 2000;275(19):14608-14614.
124. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334(26):1717-1725.
125. Buckley CA, Rouhani FN, Kaler M, Adamik B, Hawari FI, Levine SJ. Amino-terminal TACE prodomain attenuates TNFR2 cleavage independently of the cysteine switch. Am J Physiol Lung Cell Mol Physiol. 2005;288(6):L1132-L1138.
126. Fortunato SJ, Lombardi SJ, Menon R. Racial disparity in membrane response to infectious stimuli: a possible explanation for observed differences in the incidence of prematurity. Community Award Paper. Am J Obstet Gynecol. 2004;190(6):1557-1562.
127. Menon R, Velez DR, Thorsen P, et al. Ethnic differences in key candidate genes for spontaneous preterm birth: TNF-alpha and its receptors. Hum Hered. 2006;62(2):107-118.
128. Moore S, Ide M, Randhawa M, Walker JJ, Reid JG, Simpson NA. An investigation into the association among preterm birth, cytokine gene polymorphisms and periodontal disease. BJOG. 2004;111(2): 125-132.
129. Velez DR, Fortunato SJ, Morgan N, et al. Patterns of cytokine profiles differ with pregnancy outcome and ethnicity. Hum Reprod. 2008;23(8):1902-1909.
130. Velez DR, Menon R, Thorsen P, et al. Ethnic differences in interleukin 6 (IL-6) and IL6 receptor genes in spontaneous preterm birth and effects on amniotic fluid protein levels. Ann Hum Genet. 2007; 71(Pt 5):586-600.
131. Jones NM, Holzman C, Friderici KH, et al. Interplay of cytokine polymorphisms and bacterial vaginosis in the etiology of preterm delivery. J Reprod Immunol. 2010;87(1-2):82-89.
132. Sturm-Ramirez K, Gaye-Diallo A, Eisen G, Mboup S, Kanki PJ. High levels of tumor necrosis factor-alpha and interleukin-1beta in bacterial vaginosis may increase susceptibility to human immunodeficiency virus. J Infect Dis. 2000;182(2):467-473.
133. Hedges SR, Barrientes F, Desmond RA, Schwebke JR. Local and systemic cytokine levels in relation to changes in vaginal flora. J Infect Dis. 2006;193(4):556-562.
134. Oner C, Schatz F, Kizilay G et al. Progestin-inflammatory cytokine interactions affect matrix metalloproteinase-1 and -3 expression in term decidual cells: implications for treatment of chorioamnionitisinduced preterm delivery. J Clin Endocrinol Metab. 2008;93(1): 252-259.
135. Arechavaleta-Velasco F, Ogando D, Parry S, Vadillo-Ortega F. Production of matrix metalloproteinase-9 in lipopolysaccharide-stimulated human amnion occurs through an autocrine and paracrine proinflammatory cytokine-dependent system. Biol Reprod. 2002;67(6): 1952-1958.
136. Nesin M, Cunningham-Rundles S. Cytokines and neonates. Am J Perinatol. 2000;17(8):393-404.
137. Keelan JA, Blumenstein M, Helliwell RJ, Sato TA, Marvin KW, Mitchell MD. Cytokines, prostaglandins and parturition - a review. Placenta. 2003;24 Suppl A:S33-S46.
138. Hagberg H, Mallard C, Jacobsson B. Role of cytokines in preterm labour and brain injury. BJOG. 2005;112 Suppl 1:16-18.
139. Goldenberg RL, Goepfert AR, Ramsey PS. Biochemical markers for the prediction of preterm birth. Am J Obstet Gynecol. 2005; 192(5 Suppl):S36-S46.
140. Park JS, Park CW, Lockwood CJ, Norwitz ER. Role of cytokines in preterm labor and birth. Minerva Ginecol. 2005;57(4):349-366.
141. Spong CY, Scherer DM, Ghidini A, Pezzullo JC, Salafia CM, Eglinton GS. Midtrimester amniotic fluid tumor necrosis factoralpha does not predict small-for-gestational-age infants. Am J Reprod Immunol. 1997;37(3):236-239.
142. Hahn-Zoric M, Hagberg H, Kjellmer I, Ellis J, Wennergren M, Hanson LA. Aberrations in placental cytokine mRNA related to intrauterine growth retardation. Pediatr Res. 2002;51(2):201-206.
143. Huang HC, Wang CL, Huang LT, et al. Association of cord blood cytokines with prematurity and cerebral palsy. Early Hum Dev. 2004; 77(1-2):29-36.
144. Neta GI, von Ehrenstein OS, Goldman LR, et al. Umbilical cord serum cytokine levels and risks of small-for-gestational-age and preterm birth. Am J Epidemiol. 2010;171(8):859-867.
145. Redman CW, Sargent IL. Immunology of pre-eclampsia. Am J Reprod Immunol. 2010;63(6):534-543.
146. Rusterholz C, Hahn S, Holzgreve W. Role of placentally produced inflammatory and regulatory cytokines in pregnancy and the etiology of preeclampsia. Semin Immunopathol. 2007;29(2): 151-162.
147. Vural P, Degirmencioglu S, Saral NY, et al. Tumor necrosis factor alpha, interleukin-6 and interleukin-10 polymorphisms in preeclampsia. J Obstet Gynaecol Res. 2010;36(1):64-71.
148. Matthiesen L, Berg G, Ernerudh J, Ekerfelt C, Jonsson Y, Sharma S. Immunology of preeclampsia. Chem Immunol Allergy. 2005;89:49-61.
149. Jonsson Y, Matthiesen L, Berg G, Ernerudh J, Nieminen K, Ekerfelt C. Indications of an altered immune balance in preeclampsia: a decrease in in vitro secretion of IL-5 and IL-10 from blood mononuclear cells and in blood basophil counts compared with normal pregnancy. J Reprod Immunol. 2005;66(1):69-84.
150. Kupferminc MJ, Peaceman AM, Wigton TR, Tamura RK, Rehnberg KA, Socol ML. Immunoreactive tumor necrosis factor-alpha is elevated in maternal plasma but undetected in amniotic fluid in the second trimester. Am J Obstet Gynecol. 1994;171(4):976-979.
151. Jonsson Y, Ruber M, Matthiesen L, et al. Cytokine mapping of sera from women with preeclampsia and normal pregnancies. J Reprod Immunol. 2006;70(1-2):83-91.
152. Vince GS, Starkey PM, Austgulen R, Kwiatkowski D, Redman CW. Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol. 1995;102(1):20-25.
153. Mansouri R, Akbari F, Vodjgani M, Mahboudi F, Kalantar F, Mirahmadian M. Serum cytokines profiles in Iranian patients with preeclampsia. Iran J Immunol. 2007;4(3):179-185.
154. Tosun M, Celik H, Avci B, Yavuz E, Alper T, Malatyalioglu E. Maternal and umbilical serum levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in normal pregnancies and in pregnancies complicated by preeclampsia. J Matern Fetal Neonatal Med. 2010;23(8):880-886.
155. Williams MA, Farrand A, Mittendorf R, et al. Maternal second trimester serum tumor necrosis factor-alpha-soluble receptor p55 (sTNFp55) and subsequent risk of preeclampsia. Am J Epidemiol. 1999;149(4):323-329.
156. Leal AM, Poon LC, Frisova V, Veduta A, Nicolaides KH. First-trimester maternal serum tumor necrosis factor receptor-1 and pre-eclampsia. Ultrasound Obstet Gynecol. 2009;33(2):135-141.
157. Jauniaux E, Poston L, Burton GJ. Placental-related diseases of pregnancy: Involvement of oxidative stress and implications in human evolution. Hum Reprod Update. 2006;12(6):747-755.
158. Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol. 2002;2(9):656-663.
159. Szekeres-Bartho J. Regulation of NK cell cytotoxicity during pregnancy. Reprod Biomed Online. 2008;16(2):211-217.
160. Meisser A, Chardonnens D, Campana A, Bischof P. Effects of tumour necrosis factor-alpha, interleukin-1 alpha, macrophage colony stimulating factor and transforming growth factor beta on trophoblastic matrix metalloproteinases. Mol Hum Reprod. 1999;5(3): 252-260.
161. Roth I, Fisher SJ. IL-10 is an autocrine inhibitor of human placental cytotrophoblast MMP-9 production and invasion. Dev Biol. 1999;205(1):194-204.
162. Lash GE, Otun HA, Innes BA, Bulmer JN, Searle RF, Robson SC. Inhibition of trophoblast cell invasion by TGFB1, 2, and 3 is associated with a decrease in active proteases. Biol Reprod. 2005;73(2):374-381.
163. Leisser C, Saleh L, Haider S, Husslein H, Sonderegger S, Knofler M. Tumour necrosis factor-alpha impairs chorionic gonadotrophin betasubunit expression and cell fusion of human villous cytotrophoblast. Mol Hum Reprod. 2006;12(10):601-609.
164. Otun HA, Lash GE, Innes BA, et al. Effect of tumour necrosis factoralpha in combination with interferon-gamma on first trimester extravillous trophoblast invasion. J Reprod Immunol. 2011;88(1):1-11.
165. Munno I, Chiechi LM, Lacedra G, et al. Spontaneous and induced release of prostaglandins, interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha by placental tissue from normal and preeclamptic pregnancies. Am J Reprod Immunol. 1999;42(6):369-374.
166. Rinehart BK, Terrone DA, Lagoo-Deenadayalan S, et al. Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia. Am J Obstet Gynecol. 1999;181(4):915-920.
167. Bauer S, Pollheimer J, Hartmann J, Husslein P, Aplin JD, Knofler M. Tumor necrosis factor-alpha inhibits trophoblast migration through elevation of plasminogen activator inhibitor-1 in first-trimester villous explant cultures. J Clin Endocrinol Metab. 2004;89(2):812-822.
168. Renaud SJ, Postovit LM, Macdonald-Goodfellow SK, McDonald GT, Caldwell JD, Graham CH. Activated macrophages inhibit human cytotrophoblast invasiveness in vitro. Biol Reprod. 2005;73(2): 237-243.
169. Malek A, Sager R, Schneider H. Effect of hypoxia, oxidative stress and lipopolysaccharides on the release of prostaglandins and cytokines from human term placental explants. Placenta. 2001;22 Suppl A: S45-S50.
170. Garcia-Lloret MI, Winkler-Lowen B, Guilbert LJ. Monocytes adhering by LFA-1 to placental syncytiotrophoblasts induce local apoptosis via release of TNF-alpha. A model for hematogenous initiation of lacental inflammations. J Leukoc Biol. 2000;68(6):903-908.
171. Seki H, Matuoka K, Inooku H, Takeda S. TNF-alpha from monocyte of patients with pre-eclampsia-induced apoptosis in human trophoblast cell line. J Obstet Gynaecol Res. 2007;33(4):408-416.
172. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood. 2006;108(1):253-261.
173. Zenclussen AC, Gerlof K, Zenclussen ML, et al. Regulatory T cells induce a privileged tolerant microenvironment at the fetal-maternal interface. Eur J Immunol. 2006;36(1):82-94.
174. Redman CW, Sargent IL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response - a review. Placenta. 2003;24 Suppl A: S21-S27.
175. Xie F, Hu Y, Turvey SE, et al. Toll-like receptors 2 and 4 and the cryopyrin inflammasome in normal pregnancy and pre-eclampsia. BJOG. 2010;117(1):99-108.
176. Mortaz E, Redegeld FA, Nijkamp FP, Wong HR, Engels F. Acetylsalicylic acid-induced release of HSP70 from mast cells results in cell activation through TLR pathway. Exp Hematol. 2006;34(1):8-18.
177. Xie F, Turvey SE, Williams MA, Mor G, von DP. Toll-like receptor signaling and pre-eclampsia. Am J Reprod Immunol. 2010;63(1):7-16.
178. Xie F, Hu Y, Speert DP, et al. Toll-like receptor gene polymorphisms and preeclampsia risk: a case-control study and data synthesis. Hypertens Pregnancy. 2010;29(4):390-398.
179. Greer IA, Lyall F, Perera T, Boswell F, Macara LM. Increased concentrations of cytokines interleukin-6 and interleukin-1 receptor antagonist in plasma of women with preeclampsia: a mechanism for endothelial dysfunction? Obstet Gynecol. 1994;84(6):937-940.
180. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fmslike tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649-658.
181. Levine RJ, Karumanchi SA. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol. 2005;48(2):372-386.
182. Groten T, Kreienberg R, Fialka I, Huber L, Wedlich D. Altered subcellular distribution of cadherin-5 in endothelial cells caused by the serum of pre-eclamptic patients. Mol Hum Reprod. 2000;6(11): 1027-1032.
183. LaMarca B, Wallace K, Granger J. Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia. Curr Opin Pharmacol. 2011;11(2):175-179.
184. Lamarca B. The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia. Minerva Ginecol. 2010;62(2):105-120.
185. Tranquilli AL, Landi B, Corradetti A, et al. Inflammatory cytokines patterns in the placenta of pregnancies complicated by HELLP (hemolysis, elevated liver enzyme, and low platelet) syndrome. Cytokine. 2007;40(2):82-88.
186. LaMarca BD, Chandler DL, Grubbs L, et al. Role of sex steroids in modulating tumor necrosis factor alpha-induced changes in vascular function and blood pressure. Am J Hypertens. 2007;20(11):1216-1221.
187. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592-1594.
188. Wallace K, Richards S, Dhillon P, et al. CD4+ T-helper cells stimulated in response to placental ischemia mediate hypertension during pregnancy. Hypertension. 2011;57(5):949-955.
189. Dusse LM, Rios DR, Pinheiro MB, Cooper AJ, Lwaleed BA. Pre-eclampsia: relationship between coagulation, fibrinolysis and inflammation. Clin Chim Acta. 2011;412(1-2):17-21.
190. Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R. Meta- analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010; 30(4):339-353.
191. Lee TW, Fedorak RN. Tumor necrosis factor-alpha monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. Gastroenterol Clin North Am. 2010;39(3):543-557.
192. Grimm M, Lazariotou M, Kircher S, et al. Tumor necrosis factor-alpha is associated with positive lymph node status in patients with recurrence of colorectal cancer - indications for anti-TNF-alpha agents in cancer treatment. Anal Cell Pathol (Amst). 2010.
193. Toussirot E, Streit G, Wendling D. Infectious complications with anti- TNFalpha therapy in rheumatic diseases: a review. Recent Pat Inflamm Allergy Drug Discov. 2007;1(1):39-47.
194. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)- alpha therapy. Rheumatology (Oxford). 2007;46(4):695-698.
195. Chambers CD, Johnson DL, Jones KL, The OTIS Collaborative Research Group. Pregnancy outcome in women exposed to Anti-TNFalpha medication: the OTIS rheumatoid arthritis in pregnancy study. Arthritis and Rheumatism. 2004:50(90).
196. Wibaux C, Andrei I, Paccou J, et al. Pregnancy during TNFalpha antagonist therapy: beware the rifampin-oral contraceptive interaction. Report of two cases. Joint Bone Spine. 2010;77(3):268-270.
197. Ali YM, Kuriya B, Orozco C, Cush JJ, Keystone EC. Can tumor necrosis factor inhibitors be safely used in pregnancy? J Rheumatol. 2010;37(1):9-17.
198. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol. 2009;36(3):635-641.
199. Osting VC, Carter JD. A safety assessment of tumor necrosis factor antagonists during pregnancy. Expert Opin Drug Saf. 2010;9(3): 421-429.
200. Winger EE, Reed JL, Ashoush S, Ahuja S, El-Toukhy T, Taranissi M. Treatment with adalimumab (Humira) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol. 2009;61(2):113-120.
201. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med. 2007;204(1):33-39.
202. Clark DA. Should anti-TNF-alpha therapy be offered to patients with infertility and recurrent spontaneous abortion? Am J Reprod Immunol. 2009;61(2):107-112.
203. Clark DA. Anti-TNFalpha therapy in immune-mediated subfertility: state of the art. J Reprod Immunol. 2010;85(1):15-24.
204. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL. Anti- TNF-alpha therapies: the next generation. Nat Rev Drug Discov. 2003;2(9):736-746.
205. MacEwan DJ. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal. 2002;14(6):477-492.
206. Calleja-Agius J, Muttukrishna S, Pizzey AR, Jauniaux E. Pro- and antiinflammatory cytokines in threatened miscarriages. Am J Obstet Gynecol. In press. 2011.